The Efficacy of Intravitreal Aflibercept in Submacular Hemorrhage Secondary to Wet Age-related Macular Degeneration
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the efficacy of intravitreal aflibercept monotherapy in submacular hemorrhage (SMH) secondaryto wet age-related macular degeneration (AMD). Methods: This study included 25 eyes in 25 patients with SMH involving the fovea secondary to wet-AMD. Allpatients were treated with three consecutive monthly intravitreal aflibercept (2.0 mg/0.05 mL) injections, followedby as-needed reinjection. They were followed for at least 6 months. Best-corrected visual acuity (BCVA),central foveal thickness (CFT), and area of SMH were measured at diagnosis, as well as at 3 and 6 monthsafter treatment initiation. Results: The BCVA significantly improved from 0.79 ± 0.41 logarithm of the minimum angle of resolution (logMAR)at baseline to 0.54 ± 0.41 logMAR at 6 months (p < 0.001). BCVA ≥3 lines and stable vision were observed in96% of the eyes. The CFT significantly decreased from 560.8 ± 215.3 μm at baseline to 299.8 ± 160.2 μm at 6months (p < 0.001). The area of SMH significantly decreased from 10.5 ± 7.1 mm2 at baseline to 1.8 ± 6.5 mm2at 6 months (p < 0.001). The BCVA, CFT, and area of SMH at baseline, as well as duration of symptoms, allcorrelated with BCVA at the 6-month follow-up. Conclusions: Intravitreal injection of aflibercept is an effective treatment option for patients with SMH secondaryto wet-AMD; however, there may be limited efficacy in eyes with large SMH area and cases in which treatmentis delayed.
Abstract
Purpose: To evaluate the efficacy of intravitreal aflibercept monotherapy in submacular hemorrhage (SMH) secondaryto wet age-related macular degeneration (AMD). Methods: This study included 25 eyes in 25 patients with SMH involving the fovea secondary to wet-AMD. Allpatients were treated with three consecutive monthly intravitreal aflibercept (2.0 mg/0.05 mL) injections, followedby as-needed reinjection. They were followed for at least 6 months. Best-corrected visual acuity (BCVA),central foveal thickness (CFT), and area of SMH were measured at diagnosis, as well as at 3 and 6 monthsafter treatment initiation. Results: The BCVA significantly improved from 0.79 ± 0.41 logarithm of the minimum angle of resolution (logMAR)at baseline to 0.54 ± 0.41 logMAR at 6 months (p < 0.001). BCVA ≥3 lines and stable vision were observed in96% of the eyes. The CFT significantly decreased from 560.8 ± 215.3 μm at baseline to 299.8 ± 160.2 μm at 6months (p < 0.001). The area of SMH significantly decreased from 10.5 ± 7.1 mm2 at baseline to 1.8 ± 6.5 mm2at 6 months (p < 0.001). The BCVA, CFT, and area of SMH at baseline, as well as duration of symptoms, allcorrelated with BCVA at the 6-month follow-up. Conclusions: Intravitreal injection of aflibercept is an effective treatment option for patients with SMH secondaryto wet-AMD; however, there may be limited efficacy in eyes with large SMH area and cases in which treatmentis delayed.
참고문헌 (17)
- Avery R L, "Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration", Retina, 16, pp.183~189 (1996)
- Scupola A, "Natural history of macular subretinal hemorrhage in age-related macular degeneration", Ophthalmologica, 213, pp.97~102 (1999)
- Toth CA, "Fibrin directs early retinal damage after experimental subretinal hemorrhage", Arch Ophthalmol, 109, pp.723~729 (1991)
- Bakri SJ, "Photodynamic therapy for choroidal neovascularization associated with submacular hemorrhage in age-related macular degeneration", Ophthalmic Surg Lasers Imaging, 37, pp.278~283 (2006)
- Hassan AS, "Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement", Ophthalmology, 106, pp.1900~1906 (1999)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Stifter E, "Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage", Am J Ophthalmol, 144, pp.886~892 (2007)
- Shienbaum G, "Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy", Am J Ophthalmol, 155, pp.1009~1013 (2013)
- Altaweel MM, "Outcomes of eyes with lesions composed of >50% blood in the comparison of Age-related Macular Degeneration Treatments Trials (CATT)", Ophthalmology, 122, pp.391~398 (2015)
- Stewart MW, "Aflibercept", Nat Rev Drug Discov, 11, pp.269~270 (2012)
- Heier JS, "Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration", Ophthalmology, 119, pp.2537~2548 (2012)
- Cho H, "Aflibercept for exudative AMD with persistent fluid on ranibizumab and", or bevacizumab, 2013, pp.97, 1032~1035
- Kim JH, "Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage f rom choroidal neovascularization", Ophthalmology, 121, pp.926~935 (2014)
- Inoue M, "Shortterm efficacy of intravitreal aflibercept in treatment-naive patients with polypoidal choroidal vasculopathy", Retina, 34, pp.2178~2184 (2014)
- Yamamoto A, "One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy", Ophthalmology, 122, pp.1866~1872 (2015)
- Iacono P, "Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration", Retina, 34, pp.281~287 (2014)
- Cho HJ, "Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy", Am J Ophthalmol, 156, pp.524~531 (2013)